Medicine for Defiance and Aggression: What It Can Do

Key takeaways

• No medicine is FDA approved for ODD, conduct disorder, or PTSD in children.
• Medicine should aim at a clear, measurable target, such as ADHD symptoms or severe aggression, with a plan to track it.
• When ADHD is present, stimulant medicines have the strongest evidence for reducing oppositional behavior and aggression.
• Therapy and parent training stay in place. Every medicine needs a monitoring plan and a plan for stopping.

A dimmer switch can turn one lamp down. It cannot rewire the house. Medicine for a child’s behavior works in a similar way. It can lower one specific problem, such as ADHD restlessness, panic, or explosive aggression. It does not change the daily patterns between a child and the adults around them. Parent training, school supports, and therapy do that work.

This is Part 4 of a four-part series. Part 1 covers how to read a child’s hard behavior. Part 2 covers ODD. Part 3 covers conduct disorder.

This article explains options to discuss with a prescriber. It does not give doses. Never start, change, or stop a child’s medicine without the prescriber.

Start with a target you can count

Before a child starts a medicine, you need five things. These are a diagnosis, a clear target, a starting measurement, a talk about other options, and a monitoring plan.

“Less angry” is hard to measure. “Hitting drops from five times a week to one or fewer” is a target you can track. Write the target down before the first dose. Use the same measure at every visit.

Zoom

What medicine can and cannot do

When ADHD is part of the picture

Many children with ODD or conduct problems also have ADHD. Treating the ADHD can reduce the arguing and aggression too.

A 2015 analysis pooled trials in children and teens with ADHD, ODD, or conduct disorder. Stimulant medicines had a moderate to large effect on arguing, rule-breaking, and aggression. That evidence was strong. Atomoxetine had a small effect. Guanfacine had a small to moderate effect. Clonidine had a small effect, and that evidence was very weak.7 A Canadian guideline strongly recommends stimulants for this use and gives weaker, conditional support to the other three.8

Each of these medicines has its own safety profile:

• Stimulants, such as methylphenidate and amphetamine products, carry a boxed warning about misuse and addiction. Labels also warn about raised heart rate and blood pressure, slowed growth, mood or psychotic symptoms, and new or worsening tics.9 In 2025, the FDA added warnings to extended-release stimulants about higher drug levels, more side effects, and significant weight loss in children younger than 6. These products are not approved for that age group.10
• Atomoxetine carries a boxed warning about suicidal thoughts and behaviors in children and teens. Its label also warns about severe liver injury.11
• Guanfacine and clonidine extended-release can cause sleepiness, dizziness, low blood pressure, slow pulse, and fainting. Stopping suddenly can cause a rebound rise in blood pressure, so they are tapered.12,13

For a side-by-side look, see ADHD medications compared.

Severe aggression

UK guidance advises against medicine for routine management of behavior problems. Some young people have severe aggression and explosive anger that therapy and family treatment have not helped. For them, a specialist may consider short-term risperidone. The guidance calls for a review at three to four weeks and stopping at six weeks if there is no clear benefit.1

A Cochrane review looked at 10 trials with 896 young people ages 5 to 18. Risperidone reduced aggression, though that evidence was weak. It also reduced conduct problems, with moderate evidence. The review also found about 2.4 kilograms (about 5 pounds) more weight gain than placebo.14 Risperidone is not FDA approved for ODD or conduct disorder, so this use is off-label. Its pediatric approvals are irritability associated with autism (ages 5 to 17), schizophrenia (ages 13 to 17), and bipolar I mania (ages 10 to 17).15 The autism approval covers aggression as one symptom of that irritability, not aggression in ODD or conduct disorder.

The risperidone label warns about weight gain, higher blood sugar and cholesterol, and movement problems such as tardive dyskinesia. It also warns about high levels of the hormone prolactin and dizziness when standing up.15 Monitoring usually includes weight, waist size, blood pressure, blood sugar or A1c, cholesterol, and a movement exam. NICE sets the schedule: before the first dose, record weight and height on a growth chart, waist and hip size, pulse and blood pressure, fasting blood sugar or A1c, cholesterol, prolactin, and a movement exam. During treatment, check weight and height weekly, and repeat the blood sugar or A1c, cholesterol, prolactin, and movement checks throughout, especially while the dose is being adjusted.1

The Cochrane review found little evidence for other antipsychotics.14 The Canadian guideline gives valproate only weak support, based on weak evidence. It advises against lithium and carbamazepine for this use.8 Valproate also has boxed warnings. They cover liver damage, an inflamed pancreas, and serious harm to an unborn baby.16

Trauma symptoms

Trauma-focused therapy is the first-line treatment for PTSD in children.3 Medicine research is thin.

• A 10-week trial of sertraline in 131 children and teens ages 6 to 17 with PTSD found it did not work better than placebo.17
• For nightmares, a review of prazosin in children found only six case reports.18
• A 2024 review of guanfacine and clonidine for pediatric PTSD found seven case reports and three small open-label studies, with no placebo-controlled trials.19

A child with PTSD may still need medicine for a separate diagnosis, such as ADHD or depression. Trauma therapy should continue alongside it.

Anxiety

A guideline from the American Academy of Child and Adolescent Psychiatry recommends CBT and SSRIs for childhood anxiety. It suggests the two together may work better than either one alone.4 In a large trial, the combination helped the most children in the short term.20

Escitalopram and duloxetine are FDA approved for generalized anxiety disorder from age 7.5,6 Sertraline was the SSRI in that trial. Its only FDA approval for children is for OCD, so using it for other anxiety is off-label.2 Off-label means an approved medicine is used for an age or condition not listed on its label. It can still be evidence-based. Ask why it was chosen.

All antidepressants carry a boxed warning. Short-term studies found a higher risk of suicidal thoughts and behaviors in children, teens, and young adults. Watch closely during the first few months and after any dose change.5 Labels also warn about bleeding, serotonin syndrome, and mania. Stopping suddenly can cause withdrawal-like symptoms.5 Duloxetine also requires blood pressure checks and warns about liver injury.6

Medicines with weak or narrow roles

• Benzodiazepines are not routine treatment for childhood anxiety or PTSD. The FDA boxed warning covers misuse, addiction, physical dependence, and withdrawal.21 The anxiety guideline found only one poor-quality trial in children.4
• Hydroxyzine is labeled for anxiety, but its effectiveness beyond four months has not been studied. It can cause sleepiness, and heart rhythm changes (QT prolongation) have been reported.22
• Propranolol is sometimes used for performance situations such as public speaking.23 Its label says safety and effectiveness in children have not been established, and it should not be used in people with asthma or certain slow heart rhythms.24
• Buspirone did not work better than placebo in two trials of 559 children and teens ages 6 to 17 with generalized anxiety disorder.25
• Antipsychotics should not be used for ordinary anxiety, trauma symptoms, or defiance that is not dangerous.

What to watch for by medicine type

Questions to ask before starting

• What exact diagnosis and target are we treating?
• Which therapy or parent program continues alongside it?
• Is this use FDA approved for my child’s age and condition, or off-label?
• What change should we see, and by when?
• What are the common side effects, and what are the serious ones?
• What checks are needed first, such as vital signs, weight, labs, or an ECG?
• What should make us call you today, go to urgent care, or call 911?
• How will we stop if it does not help?

The free printable family worksheet packet (PDF, 7 pages) includes a medication benefit and side-effect tracker. Medication questions deserve data, not shame offers more help with this conversation.

Stopping and storing medicines safely

Do not stop an SSRI, SNRI, guanfacine, or clonidine suddenly. Their labels call for a gradual taper.5,6,12,13 Talk with the prescriber before stopping any medicine. The exception is when the prescriber or an emergency clinician tells you to stop right away.

Keep all medicines locked, especially stimulants. Count pills if misuse or overdose is a worry.

What is known and what is not

Known: Stimulants reduce oppositional behavior and aggression in children with ADHD.7 In short-term trials, risperidone reduced conduct problems (moderate evidence) and may reduce aggression (weak evidence), at the cost of weight gain.14 CBT and SSRIs help childhood anxiety.4

Less certain: Most medicine trials for disruptive behavior and trauma are short, so long-term benefit and harm are less clear.14,17,19 Medicine evidence for PTSD in children is weak.17,19

When to seek urgent help

Watch closely after starting or changing an antidepressant. Call the prescriber promptly for new agitation, restlessness, trouble sleeping, strange behavior, or new suicidal thoughts.5

Call 911 for fainting, a seizure, trouble breathing, severe confusion, or high fever with stiff muscles.

For suicidal thoughts or a mental health crisis:

• Call or text 988.26

For a possible overdose or a child who swallowed someone else’s medicine:

• Call Poison Control at 1-800-222-1222. Call 911 for severe symptoms.27

Frequently asked questions

Is risperidone a calming pill for defiance?

No. UK guidance limits it to severe aggression that therapy and family treatment have not helped. Use is short-term, with close monitoring.1 It is not a treatment for everyday defiance.

Can medicine replace parent training?

No. UK guidance advises against medicine for routine management of behavior problems.1 When ADHD is present, medicine treats the ADHD. Parent training teaches the skills, and those still have to be practiced.

What does off-label mean?

It means a medicine approved for some uses is prescribed for an age, condition, or form not listed on its label. Off-label use can be supported by research. Your prescriber should explain the reason and the evidence.

How long before we know if it is working?

It depends on the medicine. SSRIs often take several weeks. For risperidone in severe aggression, UK guidance calls for a review at three to four weeks.1 Ask your prescriber for the expected window before you start.

Why does the prescriber keep checking weight and blood pressure?

Many of these medicines can affect growth, appetite, heart rate, blood pressure, or blood sugar. Regular checks catch problems early.9,12,15

Can we stop once things get better?

Plan that with the prescriber. Some medicines need a slow taper, and symptoms can return. A planned review is safer than stopping on your own.

Related reading on NP FADY

• Defiance or Fear: How to Read a Child’s Hard Behavior
• ODD in Children: When Arguing Becomes a Pattern
• When Rule-Breaking Turns Serious: Conduct Disorder
• Medication Questions Deserve Data, Not Shame in Either Direction
• ADHD Medications Compared: Stimulants vs. Non-Stimulants for Kids and Adults
• Aggression and Self-Injury in Autism: Assessment, Safety, and Medication

References

1. National Institute for Health and Care Excellence. Antisocial behaviour and conduct disorders in children and young people: recognition and management. Clinical guideline CG158. 2013, updated April 2017. Accessed September 16, 2026. nice.org.uk

2. US Food and Drug Administration. Zoloft (sertraline hydrochloride) prescribing information. Revised 2023. Accessed September 16, 2026. accessdata.fda.gov

3. National Institute for Health and Care Excellence. Post-traumatic stress disorder. NICE guideline NG116. December 5, 2018. Accessed September 16, 2026. nice.org.uk

4. Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005. PMID 32439401.

5. US Food and Drug Administration. Lexapro (escitalopram) prescribing information. Supplement 058, April 2024. Accessed September 16, 2026. accessdata.fda.gov

6. US Food and Drug Administration. Cymbalta (duloxetine delayed-release capsules) prescribing information. Revised August 2023. Accessed September 16, 2026. accessdata.fda.gov

7. Pringsheim T, Hirsch L, Gardner D, Gorman DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry. 2015;60(2):42-51. doi:10.1177/070674371506000202. PMID 25886655.

8. Gorman DA, Gardner DM, Murphy AL, et al. Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder. Can J Psychiatry. 2015;60(2):62-76. doi:10.1177/070674371506000204. PMID 25886657.

9. US Food and Drug Administration. Ritalin (methylphenidate hydrochloride) prescribing information. Revised February 2025. Accessed September 16, 2026. accessdata.fda.gov

10. US Food and Drug Administration. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD. Drug Safety Communication. June 2025. Accessed September 16, 2026. fda.gov

11. US Food and Drug Administration. Strattera (atomoxetine) prescribing information. Supplement 053, June 2026. Accessed September 16, 2026. accessdata.fda.gov

12. US Food and Drug Administration. Intuniv (guanfacine extended-release) prescribing information. 2019. Accessed September 16, 2026. accessdata.fda.gov

13. US Food and Drug Administration. Kapvay (clonidine hydrochloride extended-release) prescribing information. 2020. Accessed September 16, 2026. accessdata.fda.gov

14. Loy JH, Merry SN, Hetrick SE, Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths. Cochrane Database Syst Rev. 2017;8(8):CD008559. doi:10.1002/14651858.CD008559.pub3. PMID 28791693.

15. Risperdal (risperidone) tablets and orally disintegrating tablets. Prescribing information. Janssen Pharmaceuticals. Label effective May 28, 2026 (SPL version 45). DailyMed, US National Library of Medicine. Accessed September 26, 2026. dailymed.nlm.nih.gov

16. US Food and Drug Administration. Depakote (divalproex sodium) prescribing information. Revised March 2026. Accessed September 16, 2026. accessdata.fda.gov

17. Robb AS, Cueva JE, Sporn J, Yang R, Vanderburg DG. Sertraline treatment of children and adolescents with posttraumatic stress disorder: a double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2010;20(6):463-471. doi:10.1089/cap.2009.0115. PMID 21186964.

18. Akinsanya A, Marwaha R, Tampi RR. Prazosin in children and adolescents with posttraumatic stress disorder who have nightmares: a systematic review. J Clin Psychopharmacol. 2017;37(1):84-88. doi:10.1097/JCP.0000000000000638. PMID 27930498.

19. Jagtiani A, Gandhi R, Banga A, et al. Alpha-2 agonists in children and adolescents with post-traumatic stress disorder: a systematic review. Cureus. 2024;16(1):e53009. doi:10.7759/cureus.53009. PMID 38410304.

20. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753-2766. doi:10.1056/NEJMoa0804633. PMID 18974308.

21. US Food and Drug Administration. Benzodiazepine drug class: drug safety communication. Boxed warning updated to improve safe use. September 23, 2020. Accessed September 16, 2026. fda.gov

22. Hydroxyzine hydrochloride tablets. Prescribing information. DailyMed, US National Library of Medicine. Accessed September 16, 2026. dailymed.nlm.nih.gov

23. American Academy of Child and Adolescent Psychiatry. Anxiety Disorders: Parents’ Medication Guide. 2020. Accessed September 16, 2026. aacap.org

24. Propranolol hydrochloride tablets. Prescribing information. DailyMed, US National Library of Medicine. Accessed September 16, 2026. dailymed.nlm.nih.gov

25. Buspirone hydrochloride tablets. Prescribing information. DailyMed, US National Library of Medicine. Accessed September 16, 2026. dailymed.nlm.nih.gov

26. 988 Suicide & Crisis Lifeline. Call or text 988, or chat at 988lifeline.org. Accessed September 16, 2026. 988lifeline.org

27. Poison Control, National Capital Poison Center. Get help online or call 1-800-222-1222. Accessed September 16, 2026. poison.org

This article is for education only. It does not recommend any medicine or dose for a specific child, and it does not replace care from a licensed prescriber. Reading it does not create a clinician-patient relationship. Evidence checked through September 16, 2026.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, or chat at 988lifeline.org, available 24/7, free and confidential. En español: marque 988 y oprima 2, o envíe AYUDA al 988. Deaf or hard of hearing: 988 videophone (ASL) or TTY 711 then 988. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.